Skip to content
Disclosery

Wildcat Capital Management, LLC

Follow

13F filer, CIK 1582384, NEW YORK, NY

Wildcat Capital Management, LLC reported $252,705,410 across 8 holdings for the quarter ended 2024-12-31, in a 13F-HR filed 2025-01-29.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001999371-25-000847

Period
2024-12-31
Reported value
$253M
Holdings
8
Top 10 weight
100%
New
3
Sold out
2

Largest buys vs the previous quarter

SecurityShares changeApprox. value
GTLBnew+11,399$642K
PCORnew+8,095$607K
SILEXION THERAPEUTICS CORPnew+113,428$228K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
SKILLZ INCexited-979,848-$5.51M
SILEXION THERAPEUTICS CORPexited-1,020,852-$536K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q4 2024

Share positions as resolved from 13F-HR 0001999371-25-000847, largest first. % of portfolio is the value over $252,705,410, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ULCCFRONTIER GROUP HLDGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 28,061,351 shares; 2024Q4: 28,061,351 shares 28,061,351$200M78.95%0Timeline
RLXRLX TECHNOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 18,046,195 shares; 2024Q4: 18,046,195 shares 18,046,195$39M15.42%0Timeline
ALLOALLOGENE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,920,787 shares; 2024Q4: 2,920,787 shares 2,920,787$6.22M2.46%0Timeline
URGNUROGEN PHARMA LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 495,606 shares; 2024Q4: 495,606 shares 495,606$5.28M2.09%0Timeline
KRONOS BIO INCKRONOS BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,297,959 shares; 2024Q4: 1,297,959 shares 1,297,959$1.23M0.49%0
GTLBGITLAB INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 11,399 shares 11,399$642K0.25%newTimeline
PCORPROCORE TECHNOLOGIES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 8,095 shares 8,095$607K0.24%newTimeline
SILEXION THERAPEUTICS CORPSILEXION THERAPEUTICS CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 113,428 shares 113,428$228K0.09%new

Sold out in Q4 2024

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
SKILLZ INCSKILLZ INC979,848$5.51Mshares
SILEXION THERAPEUTICS CORPSILEXION THERAPEUTICS CORP1,020,852$536Kshares

How Q4 2024 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001999371-25-000847 base2025-01-29acceptance time not in the bulk data set